| Clinical Study "Common" Name (formal title) | Number of enrollees | Funding source (pharma/NIH) | Year complete | Primary publication | Full study treatment protocol |
|---|---|---|---|---|---|
| DERBY/OAKS |
Targeted: 1,200 (600, DERBY; 600, OAKS) |
Apellis Pharmaceuticals | In progress |
NCT03525613. A study to Compare the Efficacy and Safety of Intravitreal APL-2 Therapy With Sham Injections in Patients With Geographic Atrophy (GA) Secondary to Age-Related Macular Degeneration. Last update September 16, 2020. https://clinicaltrials.gov/ct2/show/NCT03525613 |
N/A |